ClinicalTrials.gg
CompletedNCT03330327Updated Nov 6, 2017

Molar Potency Study of HM12470 in Healthy Subjects

A Phase 1 interventional study of HM12470 in Healthy Subjects, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2017, 9 years 3 months ago, and no results have been posted to the registry.
  • Registered 2 years 6 months after the study started (first participant enrolled Mar 2015, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a phase 1 study to assess and compare molar potency of HM12470 and regular human insulin in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be non-pregnant and non-lactating
  • Males must be surgically sterile or using an acceptable method

Exclusion criteria

Exclusion Criteria:

  • Participation in an study within 30 days prior to dosing
  • Use of new prescription and non-prescription drugs within 3 weeks preceding the first dosing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part 1

    Intravenous (IV) infusion of HM12470

    Biological: HM12470

  • Experimental
    Part 2: Sequence 1

    Intravenous (IV) infusion of HM12470

    Biological: HM12470

  • Experimental
    Part 2: Sequence 2

    Intravenous (IV) infusion of HM12470

    Biological: HM12470

Interventions

  • BiologicalHM12470

    HM12470 is a long-acting insulin analogue

06

What researchers measure

Primary outcomes

  1. Blood glucose assessment of HM12470 and regular human insulin (RHI) over the entire dosing period

    - Comparison of HM12470 to RHI based on blood glucose profile generated by intravenous infusion

    Time frame: 1 month

Secondary outcomes

  1. Cmax of HM12470

    - Maximum concentration of HM12470 over the entire dosing period

    Time frame: 1 month

  2. AUC of HM12470

    - Area Under the Curve of HM12470 over the entire dosing period

    Time frame: 1 month

07

Study locations

1 site
  • Hanmi Investigative Site
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Aug 2017, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 6, 2017
StartActual
Mar 30, 2015
Primary completionActual
Aug 17, 2017
CompletionActual
Aug 17, 2017
Last update
Nov 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03330327
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Mar 30, 2015
Primary completion
Aug 17, 2017
Completion
Aug 17, 2017
Last update
Nov 6, 2017

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HM12470

Start the discussion